crizotinib (xalkori) Report issue

Small molecule Orphan Drug FDA Approved FDA First in Class Accelerated Approval FDA Priority Review FDA

Active Ingredient History

  • Now
Crizotinib (trade name Xalkori, Pfizer, Inc.) is an anti cancer drug approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. Crizotinib is an inhibitor of receptor tyrosine kinases including ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), ROS1 (c-ros), and Recepteur d’Origine Nantais (RON). Common adverse reactions in clinical trials with crizotinib, occurring at an incidence of 25% or higher, included visual disorders, nausea, diarrhea, vomiting, constipation, edema, elevated transaminases, and fatigue. Crizotinib is currently under investigational study for use in treatment of Uveal Melanoma.   NCATS

  • SMILES: C[C@@H](OC1=CC(=CN=C1N)C2=CN(N=C2)C3CCNCC3)C4=C(Cl)C=CC(F)=C4Cl
  • Mol. Mass: 450.337
  • ALogP: 5.04
  • ChEMBL Molecule:
More Chemistry

Drug Pricing (per unit)



United States

$208.8705 - $274.5150
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

crizotinib | crizotinibum | pf02341066 | pf 02341066 | pf-02341066 | pf-2341066 | (r)-crizotinib | xalkori


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue